Abhijeet Pataskar
Abhijeet Pataskar
1Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
1,#,
Julien Champagne
Julien Champagne
1Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
1,#,
Remco Nagel
Remco Nagel
1Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
1,#,
Juliana Kenski
Juliana Kenski
2Division of Molecular Oncology and Immunology, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
2,
Maarja Laos
Maarja Laos
3Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
4Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3,4,
Justine Michaux
Justine Michaux
5Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
6Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland
5,6,
Hui Song Pak
Hui Song Pak
5Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
6Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland
5,6,
Onno B Bleijerveld
Onno B Bleijerveld
7NKI Proteomics facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands
7,
Kelly Mordente
Kelly Mordente
1Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
1,
Jasmine Montenegro Navarro
Jasmine Montenegro Navarro
1Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
1,
Naomi Blommaert
Naomi Blommaert
1Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
1,
Morten M Nielsen
Morten M Nielsen
3Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
4Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3,4,
Domenica Lovecchio
Domenica Lovecchio
1Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
1,
Everett Stone
Everett Stone
8Department of Molecular Biosciences, University of Texas, Austin, TX USA
8,
George Georgiou
George Georgiou
8Department of Molecular Biosciences, University of Texas, Austin, TX USA
8,
Mark C de Gooijer
Mark C de Gooijer
9Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
9,
Olaf van Tellingen
Olaf van Tellingen
9Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
9,
Maarten Altelaar
Maarten Altelaar
7NKI Proteomics facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands
10Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, The Netherlands
7,10,
Robbie P Joosten
Robbie P Joosten
11Division of Biochemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands
11,
Anastassis Perrakis
Anastassis Perrakis
11Division of Biochemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands
11,
Johanna Olweus
Johanna Olweus
3Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
4Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3,4,
Michal Bassani-Sternberg
Michal Bassani-Sternberg
5Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
6Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland
5,6,
Daniel S Peeper
Daniel S Peeper
2Division of Molecular Oncology and Immunology, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
2,
Reuven Agami
Reuven Agami
1Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
12Erasmus MC, Department of Genetics, Rotterdam University, Rotterdam, The Netherlands
1,12,✉
1Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
2Division of Molecular Oncology and Immunology, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
3Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
4Institute of Clinical Medicine, University of Oslo, Oslo, Norway
5Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
6Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland
7NKI Proteomics facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands
8Department of Molecular Biosciences, University of Texas, Austin, TX USA
9Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
10Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, The Netherlands
11Division of Biochemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands
12Erasmus MC, Department of Genetics, Rotterdam University, Rotterdam, The Netherlands
Subject terms: Tumour immunology, Proteomics
© The Author(s) 2022
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.